Understanding challenges for recovery homes during COVID-19.

COVID-19 recovery home sober living house social model virus mitigation

Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
07 2021
Historique:
received: 17 06 2020
revised: 08 08 2020
accepted: 01 10 2020
pubmed: 1 11 2020
medline: 29 7 2021
entrez: 31 10 2020
Statut: ppublish

Résumé

Understanding the effects of COVID-19 mitigation for persons in group living environments is of critical importance to limiting the spread of the virus. In the U.S., residential recovery homes for persons with alcohol and drug disorders are good examples of high-risk environments where virus mitigation procedures are essential. The National Alliance for Recovery Residences (NARR) has taken recommendations developed by the Center for Disease Control (CDC) and applied them to recovery home settings. This paper describes how COVID-19 mitigation efforts in recovery homes may be influenced by two factors. First, while some houses are licensed by states with rigorous health and safety standards, others are not licensed and are subject to less oversight. These homes may be more inconsistent in adhering to mitigation standards. Second, to varying degrees, recovery homes use a social model approach to recovery that contrasts with mitigation procedures such as social distancing and stay-at-home orders. This paper provides examples of ways recovery homes have been forced to adjust to the competing demands of mitigation efforts and social model recovery. The paper also identifies multiple questions that could be addressed by provider-researcher coalitions to inform how social model recovery can navigate forward during the era of COVID-19. As we move forward during the era of COVID-19, providers are encouraged to remember that recovery homes have a history of resilience facing adversity and in fact have their origins in grassroots responses to the challenges of their times.

Identifiants

pubmed: 33127280
pii: S0955-3959(20)30324-8
doi: 10.1016/j.drugpo.2020.102986
pmc: PMC7566762
pii:
doi:

Substances chimiques

Ethanol 3K9958V90M

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

102986

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA042938
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of Interest There are no conflicts of interest to report. The study was approved by the Public Health Institute IRB.

Références

Ther Communities. 2015 Oct 01;36(3):163-172
pubmed: 26604434
Addict Res Theory. 2012 Dec 1;20(6):480-491
pubmed: 24478615
J Psychoactive Drugs. 2014 Nov-Dec;46(5):436-43
pubmed: 25364996
J Subst Use. 2021;26(2):151-155
pubmed: 33732093
J Subst Use. 2010 Jan 1;15(5):352-366
pubmed: 21197122
J Drug Issues. 2016 Jan 1;46(1):51-63
pubmed: 26834279
Int J Self Help Self Care. 2014;8(2):157-187
pubmed: 25477748
Addict Disord Their Treat. 2017 Sep;16(3):138-150
pubmed: 29056875
Cytokine Growth Factor Rev. 2020 Jun;53:1-9
pubmed: 32487439
Addiction. 2012 Jan;107(1):4-5
pubmed: 22151313
Am J Public Health. 2006 Oct;96(10):1727-9
pubmed: 17008561
N Engl J Med. 2020 Aug 6;383(6):510-512
pubmed: 32283003
Subst Abus. 2016;37(1):248-54
pubmed: 25962090
J Subst Abuse Treat. 2020 Dec;119:108094
pubmed: 32868142

Auteurs

Douglas L Polcin (DL)

Behavioral Health and Recovery Studies, Public Health Institute, 4383 Fallbrook Road, Concord, California 64521. Electronic address: dlpolcin@aol.com.

Elizabeth Mahoney (E)

Behavioral Health and Recovery Studies, Public Health Institute, 4383 Fallbrook Road, Concord, California 64521.

Friedner Wittman (F)

CLEW Associates, Berkeley, California.

Dave Sheridan (D)

National Alliance of Recovery Residences, St. Paul, Minnesota.

Amy A Mericle (AA)

Alcohol Research Group, Public Health Institute, Emeryville, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH